 |
 |
|
|
|
| Bimatoprost |
 |
| White powder |
 |
| 155206-00-1 |
 |
Bimatoprost (marketed in the U.S., Canada and Europe by Allergan, under the trade name Lumigan) is a prostaglandin analog/prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. In December 2008, the indication to lengthen eyelashes was approved by the U.S. Food and Drug Administration (FDA)
the cosmetic formulation of bimatoprost is sold as Latisse. In 2008-2011, at least three case series suggested that bimatoprost has the ability to reduce adipose (fat) tissue. |
 |
Product Name: Bimatoprost
Synonyms: N-Ethyl-9Alpha,11Alpha,15S-Trihydroxy-17-Phenyl-18,19,20-Trinor-Prosta-5Z, 13E-Dien-1-Amide
LUMIGAN
Bimatoprost(TM)
17-phenyl TRINOR prostaglandin F2ALPHA ethyl amide
CAS: 155206-00-1
MF: C25H37NO4
MW: 415.5656
Assay: 99%
Appearance: White powder
Density 1.145g/cm3
Boiling point 629.8¡ÆC at 760 mmHg
Refractive index 1.591
Flash point 334.7¡ÆC
Vapour Pressur 9.94E-17mmHg at 25¡ÆC
2. Descriptions:
Bimatoprost (marketed in the U.S., Canada and Europe by Allergan, under the trade name Lumigan) is a prostaglandin analog/prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. In December 2008, the indication to lengthen eyelashes was approved by the U.S. Food and Drug Administration (FDA)
the cosmetic formulation of bimatoprost is sold as Latisse. In 2008-2011, at least three case series suggested that bimatoprost has the ability to reduce adipose (fat) tissue. |
| Industrial field |
pharmaceutical |
|
|
 |
|
|
|
|
|
 |
| There are no existing companies to distribute selected chemical product |
|
 |
|
|
|
